Kim Seung-won Lobbying Allegations Spark Investor Anger as Sejong Medical Faces Delisting

Sejong Medical faces delisting amid investor anger over Kim Seung-won's alleged lobbying for Janssen clinical trial approval.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.